CDK4 and neoplasm: A targeted genomic analysis of 348 pretreatment tumors treated with CDK4/6i plus ET found loss-of-function mutations in FAT atypical cadherin 1 to be associated with much shortened PFS, although these mutations were only present in 1.7% of the tumor samples [4].